Additionally, there is a certain interaction between abnormal mRNA expression of SLC2A6, SLC2A8, SLC2A9 and prognosis in breast cancer (HR: 1.13 [1.06–1.62];p = 0.013, HR: 1.28 [1.03–1.59];p = 0.027 and HR: 0.78 [0.61–0.99];p = 0.043, respectively). Here, SLC2A6 is linked to breast carcinoma.